Ny artikkel i et prestisjefylt tidsskrift om LTX-315 fra en Koreansk forskergruppe som har gjort eksperimenter med de “biofysiske egenskapene” peptiden har til å ødelegge cellemembranen til celler generelt, og kreftceller spesielt. Dette er altså noe de øyensynlig har gjort bare fordi de synes LTX-315 er så spennede!
Trukket ut noen interessante partier:
“there has long been an emphasis on applying biophysical measurement strategies to characterize the corresponding membrane-peptide interactions in order to gain mechanistic insight that can be useful for eventual clinical applications. Curiously, such biophysical strategies have been widely used to study antimicrobial and antiviral peptides, however, they have not been applied to investigate one of the most clinically advanced anticancer peptides, LTX-315, until the present study. “
“From a translational viewpoint, our findings provide biophysical insight into possibly why the LTX-315 peptide selectively inhibits cancer cells over normal cells, as indicated by greater inhibitory potency towards cancer cells vs. normal cells that has been observed in in vitro testing. Indeed, it has been suggested that this selectivity to inhibit cancer cells may relate to differences in the physicochemical properties of cancer and normal cells. While anionic PS lipids are mainly located on the inner leaflet of normal cell membranes, they are present on the outer surface of cancer cell membranes, which is a prominent distinction that results in cancer cell membranes typically having greater negative surface charge than normal cell membranes and also helps cancer cells avoid being recognized as threats by the immune system.
Returning to our findings, these compositional features of cancer and normal cell membrane surfaces help to explain why LTX-315 preferentially disrupts cancer cell mem- branes due to strong electrostatic interactions and is consistent with the biophysical results observed in this study across the three tested model membrane platforms. Conversely, the outer leaflet of normal cell membranes contains high zwitterionic lipid fractions, especially PC lipids, and hence the LTX-315 peptide is more likely to interact only weakly with those membranes and not cause such intense membrane disruption, which also agrees well with our biophysical results. “
“As LTX-315 is a first-in-class anticancer peptide immunotherapy that is being explored for a wide range of cancer therapy applications in ongoing human clinical trials, it is critical to establish a strong mechanistic understanding of how LTX-315 functions and our biophysical findings provide direct evidence that the peptide preferentially and irreversibly disrupts negatively charged membranes in a manner that makes LTX-315 an excellent candidate for further clinical translation.”
Oslo børs sitt desidert høyest prisede biotekselskap har ingen vitenskapelige artikler fra de siste tre årene publisert. Fra Lytix bare renner det ut! Og Lytix har så spennede teknologi at akademikere verden over forsker og skriver artikler om den, til og med uten at de har noen direkte interesser i den videre utviklingen! Det er ganske unikt vil jeg mene. Når skal aksjemarkedet forstå dette også?
ijms-23-10558.pdf (3,8 MB)
